Browsing by Subject "Maintenance"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Augmented Reality-Assisted Deep Reinforcement Learning-Based Model towards Industrial Training and Maintenance for NanoDrop Spectrophotometer
    (MDPI, 2023-06-29) Alatawi, Hibah; Albalawi, Nouf; Shahata, Ghadah; Aljohani, Khulud; Alhakamy, A’aeshah; Tuceryan, Mihran; Computer and Information Science, School of Science
    The use of augmented reality (AR) technology is growing in the maintenance industry because it can improve efficiency and reduce costs by providing real-time guidance and instruction to workers during repairs and maintenance tasks. AR can also assist with equipment training and visualization, allowing users to explore the equipment’s internal structure and size. The adoption of AR in maintenance is expected to increase as hardware options expand and development costs decrease. To implement AR for job aids in mobile applications, 3D spatial information and equipment details must be addressed, and calibrated using image-based or object-based tracking, which is essential for integrating 3D models with physical components. The present paper suggests a system using AR-assisted deep reinforcement learning (RL)-based model for NanoDrop Spectrophotometer training and maintenance purposes that can be used for rapid repair procedures in the Industry 4.0 (I4.0) setting. The system uses a camera to detect the target asset via feature matching, tracking techniques, and 3D modeling. Once the detection is completed, AR technologies generate clear and easily understandable instructions for the maintenance operator’s device. According to the research findings, the model’s target technique resulted in a mean reward of 1.000 and a standard deviation of 0.000. This means that all the rewards that were obtained in the given task or environment were exactly the same. The fact that the reward standard deviation is 0.000 shows that there is no variability in the outcomes.
  • Thumbnail Image
    Item
    Developing Maintenance Cultures in UN Police Peacekeeping Operations
    (2017) Warner, Will; Farnworth, Morgan; Hartnett, Brendan; Foley, William A., Jr.; Cutler, Jordan; Davids, Allison; Diaz, Carmen; Hall, Hannah; Howell, Stephen; Kiilu, Joshua; Klingler, Kelsey; Laucevicius, Rachell; Taake, Tatyana
    This report provides an analysis and evaluation of maintenance cultures in United Nations Police Contributing Countries (PCC) receiving funding for Formed Police Units from the United States. The US Department of State, Bureau of International Narcotics and Law Enforcement Affairs (INL) recognized a marked lack of research on maintenance cultures in police agencies receiving foreign funding and sought to build a base of knowledge to aid in creating and sustaining maintenance cultures within these organizations. The INL also requested analysis and evaluation of maintenance cultures in five specific African PCCs (Cameroon, Ghana, Rwanda, Senegal, and Togo), as well as recommendations to create and sustain maintenance cultures specific to these countries. By establishing effective maintenance cultures, INL seeks to ensure that equipment purchased with funding from the United States will operate effectively throughout the manufacturer's estimated life-span.
  • Thumbnail Image
    Item
    Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
    (Springer Nature, 2021-08-28) Ravandi, Farhad; Roboz, Gail J.; Wei, Andrew H.; Döhner, Hartmut; Pocock, Christopher; Selleslag, Dominik; Montesinos, Pau; Sayar, Hamid; Musso, Maurizio; Figuera‑Alvarez, Angela; Safah, Hana; Tse, William; Sohn, Sang Kyun; Hiwase, Devendra; Chevassut, Timothy; Pierdomenico, Francesca; La Torre, Ignazia; Skikne, Barry; Bailey, Rochelle; Zhong, Jianhua; Beach, C. L.; Dombret, Herve; Medicine, School of Medicine
    Background: Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine maintenance therapy significantly prolonged overall survival by 9.9 months (P < 0.001) and relapse-free survival by 5.3 months (P < 0.001) compared with placebo in patients with AML in first remission after IC who were not candidates for transplant. Currently, the QUAZAR AML-001 trial provides the most comprehensive safety information associated with oral azacitidine maintenance therapy. Reviewed here are common adverse events (AEs) during oral azacitidine treatment in QUAZAR AML-001, and practical recommendations for AE management based on guidance from international cancer consortiums, regulatory authorities, and the authors' clinical experience treating patients in the trial. Methods: QUAZAR AML-001 is an international, placebo-controlled randomized phase 3 study. Patients aged ≥ 55 years with AML and intermediate- or poor-risk cytogenetics at diagnosis, who had attained first complete remission (CR) or CR with incomplete blood count recovery (CRi) within 4 months before study entry, were randomized 1:1 to receive oral azacitidine 300 mg or placebo once-daily for 14 days in repeated 28-day cycles. Safety was assessed in all patients who received ≥ 1 dose of study drug. Results: A total of 469 patients received oral azacitidine (n = 236) or placebo (n = 233). Median age was 68 years. Patients received a median of 12 (range 1-80) oral azacitidine treatment cycles or 6 (1-73) placebo cycles. Gastrointestinal AEs were common and typically low-grade. The most frequent grade 3-4 AEs during oral azacitidine therapy were hematologic events. AEs infrequently required permanent discontinuation of oral azacitidine (13%), suggesting they were effectively managed with use of concomitant medications and oral azacitidine dosing modifications. Conclusion: Oral azacitidine maintenance had a generally favorable safety profile. Prophylaxis with antiemetic agents, and blood count monitoring every other week, are recommended for at least the first 2 oral azacitidine treatment cycles, and as needed thereafter. Awareness of the type, onset, and duration of common AEs, and implementation of effective AE management, may maximize treatment adherence and optimize the survival benefits of oral azacitidine AML remission maintenance therapy.